Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
نویسندگان
چکیده
Address: 1Department of Nephrology, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany, 2Center for Cardiovascular Research, Department of Pharmacology and Toxicology, Charité, Campus Mitte, Hessische Str. 3-4, Berlin, Germany, 3Pathology, Research Centre, Bayer HealthCare, Aprather Weg 18a, Wuppertal, Germany, 4Cardiology Research, Bayer HealthCare, Aprather Weg 18a, Wuppertal, Germany, 5Martin-Luther-University, School of Pharmacy, Halle, Germany and 6Department of Pharmacology, University of Cologne, Gleueler Strasse 24, D-50931 Cologne, Germany
منابع مشابه
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
Background Pulmonary hypertension (PH) is a progressive and debilitating condition with a high rate of mortality. Riociguat (BAY 63-2521) is a new drug in development for PH that is well tolerated [1,2] and has superior efficacy to nitric oxide in patients with PH [2]. Treatment recommendations for PH are based on combination therapies that include warfarin. The aim of this study was to investi...
متن کاملNo pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
Objectives Riociguat, an oral soluble guanylate cyclase (sGC) stimulator, is a new candidate for treatment of pulmonary hypertension (PH). Riociguat increases cGMP production through a novel dual mode of action: direct NOindependent stimulation of sGC and increasing sensitivity of sGC to low levels of NO. Another sGC stimulator, BAY 41-2272, has shown anti-platelet activity in animal models, as...
متن کاملRiociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
Clinical background Despite recent advances, the prognosis for patients with pulmonary hypertension remains poor. Riociguat (BAY 63-2521) is a novel oral stimulator of the nitric oxide (NO) receptor soluble guanylate cyclase, and synergizes with low levels of bioavailable NO. Its safety and efficacy in dose titration were studied in patients with PAH (n = 33) or CTEPH (n = 42) in this multicent...
متن کاملDiscovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). Impairments of the NO-sGC signaling pathway have been implicated in the pathogenesis of cardiovascular and other diseases. Direct stimulation of sGC represents a promising therapeutic strategy particularly for the treatment of pulmonary hypertension (PH), a disabling disease associated with a poo...
متن کاملRiociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
Background A direct pharmacological stimulation of soluble guanylate cyclase (sGC) is an emerging therapeutic approach to the management of various cardiopulmonary disorders associated with endothelial dysfunction. Novel sGC stimulators, including riociguat (BAY 63-2521), have a dual mode of action: they sensitize sGC to endogenously produced nitric oxide (NO) and also directly stimulate sGC in...
متن کامل